Compare OCC & CYPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OCC | CYPH |
|---|---|---|
| Founded | 1983 | 2011 |
| Country | United States | United States |
| Employees | N/A | 6 |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.1M | 73.4M |
| IPO Year | 2001 | N/A |
| Metric | OCC | CYPH |
|---|---|---|
| Price | $10.48 | $1.00 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 244.2K | ★ 2.5M |
| Earning Date | 06-04-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 290.91 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $87,828,590.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 37.03 | N/A |
| 52 Week Low | $2.44 | $0.50 |
| 52 Week High | $13.95 | $3.70 |
| Indicator | OCC | CYPH |
|---|---|---|
| Relative Strength Index (RSI) | 50.84 | 60.44 |
| Support Level | $6.81 | $0.94 |
| Resistance Level | $11.50 | $1.01 |
| Average True Range (ATR) | 1.33 | 0.10 |
| MACD | -0.22 | 0.00 |
| Stochastic Oscillator | 26.38 | 63.99 |
Optical Cable Corp manufactures a broad range of fiber optic and copper data communication cabling and connectivity solutions for the enterprise, wireless carrier, and specialty markets. The Company offers high quality products that operate as a system solution or integrate with other components, including fiber, copper, hybrid cabling, cabinets, racks, enclosures, and deployable solutions for enterprise networks, data centers, residential, campus, Passive Optical LAN installations, and customized applications in military, industrial, mining, petrochemical, renewable energy, and broadcast industries. It operates a single reportable segment covering the design, development, manufacture, and marketing of its cabling and connectivity solutions.
Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.